AxS 007
Alternative Names: AxS-007Latest Information Update: 27 Sep 2024
At a glance
- Originator Nanocarry Therapeutics
- Developer Nanocarry Therapeutics; National Cancer Institute (USA)
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain metastases
Most Recent Events
- 04 Sep 2024 Nanocarry Therapeutics and National Cancer Institute (NCI) USA enters into a collaboration agreement for comprehensive preclinical characterization of AxS 007
- 04 Sep 2024 Preclinical trials in Brain metastases in Israel (unspecified route) prior to September 2024
- 04 Sep 2024 Preclinical trials in Brain metastases in USA (unspecified route) prior to September 2024